Elliot Page TRT: What Clinicians Should Tell Patients

What Elliot Page Has Said About Testosterone Therapy

Elliot Page came out publicly as transgender in December 2020 and discussed gender-affirming hormone therapy in subsequent interviews. In his 2023 memoir Pageboy, he described testosterone therapy as central to his sense of physical congruence, noting changes in voice, body composition, and overall well-being. He has not publicly disclosed the specific formulation, dose, or prescribing clinician, so any dose-level inference would be speculative and is not made here.

Why Patients Bring This Up in Clinic

Patients often arrive citing a celebrity's experience to ask whether that same path is available to them. The clinical value of Elliot Page's public disclosure is that it normalizes help-seeking. The risk is that patients may expect identical timelines or outcomes, which vary by individual biology, baseline hormone levels, and formulation choice.

Providers should treat these conversations as an opening to discuss the actual evidence base rather than a celebrity's subjective narrative.

Separating Public Narrative From Clinical Protocol

Page's descriptions align broadly with the documented physiological effects of exogenous testosterone. Voice deepening, increased lean mass, clitoral enlargement, and cessation of menses are all well-characterized in the literature. A 2019 review in Endocrine Reviews catalogued these changes with onset timelines [1]. Providers can validate a patient's connection to Page's story while redirecting to individualized assessment.

The Clinical Evidence Base for Gender-Affirming Testosterone Therapy

Gender-affirming hormone therapy (GAHT) with testosterone is one of the most studied interventions in transgender medicine. The evidence now spans decades and multiple study designs. Two major professional bodies, the Endocrine Society and the World Professional Association for Transgender Health (WPATH), have published guidelines that form the standard of care.

Endocrine Society and WPATH Guidelines

The Endocrine Society's 2017 Clinical Practice Guideline on Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons recommends maintaining serum testosterone in the normal male physiological range, targeting trough levels of 400 to 700 ng/dL (14 to 24 nmol/L) for transmasculine individuals [2]. WPATH Standards of Care Version 8, published in 2022, extended the evidence review and added recommendations for informed consent models of care, removing a mandatory mental health referral requirement for many adults [3].

Both guidelines state that the goals of testosterone therapy are to produce virilization consistent with a patient's gender identity while minimizing adverse effects.

Mental Health Outcomes

The mental health benefit of GAHT is among the most replicated findings in this field. A 2021 systematic review and meta-analysis published in PLOS ONE (N=3,458 participants across 19 studies) found that gender-affirming hormone therapy was associated with statistically significant reductions in depression (standardized mean difference 0.34, P<0.001) and anxiety scores compared with pre-treatment baselines [4]. Psychological distress scores also improved significantly.

These data are relevant when patients ask whether Page's reported improvement in well-being is "just placebo." It is not. The effect sizes are modest to moderate but consistent across study populations.

Physical Changes: What the Evidence Shows

A 12-month prospective study published in The Journal of Clinical Endocrinology and Metabolism (N=247 transmasculine adults) documented the following mean changes after one year of testosterone therapy [5]:

• Lean body mass increased by approximately 3.5 kg
• Fat mass decreased by approximately 2.1 kg
• Hemoglobin rose from a female-typical mean of 13.1 g/dL to 14.8 g/dL
• Total cholesterol and LDL both increased modestly (mean LDL increase 11 mg/dL)

Voice changes begin within 3 to 6 months and are largely permanent. Providers should document baseline voice quality and counsel patients that the rate of change varies.

Testosterone Formulations Used in Gender-Affirming Care

No single formulation is recommended over others in the guidelines. Choice depends on patient preference, insurance coverage, injection tolerance, and the clinical goal of steady versus cyclic hormone levels.

Injectable Testosterone

Testosterone cypionate and testosterone enanthate are the most commonly prescribed formulations in the United States for GAHT. Both are administered intramuscularly or subcutaneously. Typical starting doses range from 50 mg weekly to 100 mg every two weeks, with titration based on trough serum levels [2]. Weekly dosing produces smaller peak-to-trough fluctuations, which some patients find reduces mood variability.

Testosterone undecanoate (Aveed), a long-acting injectable given every 10 to 14 weeks after loading doses, is FDA-approved for hypogonadism in cisgender males and used off-label in some GAHT protocols [6].

Transdermal Testosterone

Testosterone gel (AndroGel 1%, 1.62%; Testim; Vogelxo) and transdermal patches (Androderm) offer a needle-free option. Serum levels are more stable than with biweekly injections but patient adherence to daily application must be assessed. Transfer to children or partners through skin contact is a documented safety concern that requires counseling [6].

Subcutaneous Pellets

Testosterone pellets (Testopel) are inserted subcutaneously every 3 to 6 months. Dose titration is less flexible once implanted. Some providers use pellets for patients who struggle with injection adherence or daily topical application.

Monitoring Protocol: A Practical Framework for Clinicians

The following monitoring framework synthesizes the Endocrine Society 2017 guideline [2] and WPATH SOC8 [3] into a practical visit schedule. Providers at practices with limited transgender care experience can use this as a starting point.

Year One: Every 3 Months

At each quarterly visit in the first year, obtain:

1. Total serum testosterone (trough, drawn just before the next injection or in the morning for daily formulations). Target 400 to 700 ng/dL per Endocrine Society guidance.
2. Hematocrit. Testosterone stimulates erythropoiesis. A hematocrit above 50% warrants dose reduction or formulation change. The FDA label for testosterone products carries a warning regarding polycythemia [6].
3. Blood pressure. Cardiovascular risk monitoring is essential; transmasculine individuals on testosterone show modest increases in systolic blood pressure over time.
4. Weight and BMI. Track body composition changes and screen for metabolic syndrome.

Dose adjustments are made based on trough testosterone results and the presence or absence of desired virilization.

After Year One: Every 6 to 12 Months

Once testosterone levels are stable and within range, monitoring frequency reduces. At each annual visit, add:

• Fasting lipid panel (LDL tends to rise; HDL may fall modestly)
• Hemoglobin A1c if the patient has risk factors for type 2 diabetes
• Pap smear per current screening guidelines; the cervix remains present unless hysterectomy has occurred
• Bone density (DXA) at baseline and every 2 years if gonadectomy has occurred, because testosterone dose adequacy for bone protection must be confirmed

When to Refer

Refer to endocrinology if:

• Hematocrit exceeds 54% despite dose reduction
• Testosterone levels remain <300 ng/dL at trough on adequate doses, suggesting absorption or compliance issues
• The patient develops signs of polycythemia vera requiring hematology workup
• Fertility preservation questions arise that exceed the provider's scope

Fertility Counseling Before Starting Testosterone

Testosterone suppresses ovulation in most patients within the first few months of therapy, but it does not reliably prevent pregnancy. The American Society for Reproductive Medicine (ASRM) and WPATH SOC8 both state that fertility preservation counseling must occur before initiating GAHT [3, 7].

Oocyte or embryo cryopreservation is the most effective fertility preservation option for transmasculine patients before gonadectomy. Ovarian tissue cryopreservation remains experimental but is available at some centers.

Patients must also be counseled that if they wish to conceive, testosterone therapy must be discontinued, and ovulation may or may not return. A 2019 case series in Fertility and Sterility reported successful pregnancies in transmasculine individuals who paused testosterone, though menstrual resumption timelines varied from 1 to 12 months [8].

Cardiovascular and Hematologic Risk: What the Data Show

The cardiovascular risk profile of long-term testosterone therapy in transmasculine individuals remains an active area of research. Current data are reassuring but not definitive, largely because most cohort studies have follow-up periods under 10 years.

Polycythemia

Erythrocytosis is the most consistently reported hematologic adverse effect. A cross-sectional study published in Transgender Health (N=183) found hematocrit above 50% in approximately 17% of transmasculine patients on testosterone [9]. Risk is higher with injectable formulations and higher doses. Providers should not dismiss an elevated hematocrit as trivial; polycythemia raises whole-blood viscosity and increases thromboembolic risk.

Lipid Changes

As noted above, LDL tends to rise and HDL tends to fall modestly with testosterone therapy. The clinical significance over decades is unclear. The American Heart Association's guidance on lipid management applies equally here: if LDL exceeds 190 mg/dL, statin therapy should be considered regardless of the underlying cause [10].

Cardiovascular Events

A large population-based study from the Netherlands (N=2,671 transgender men followed for a mean of 8 years) found no significant increase in myocardial infarction or stroke rates compared with the general female population, though venous thromboembolism rates were modestly elevated [11]. Providers should weigh this in patients with preexisting clotting disorders or prolonged immobility.

Informed Consent: What Patients Need to Understand

The informed consent model, now endorsed by WPATH SOC8, means that a standalone mental health letter is not required for most adults seeking GAHT [3]. The prescribing clinician carries the responsibility for documenting that the patient understands the expected effects, the uncertain effects, and the irreversible effects.

Required Discussion Points

The Endocrine Society guideline specifies that informed consent must cover [2]:

• Expected effects (voice deepening, clitoral enlargement, cessation of menses, increased body hair, scalp hair thinning in genetically predisposed patients)
• Uncertain or variable effects (libido changes, acne severity, timeline of virilization)
• Irreversible effects (voice changes and clitoral growth do not fully reverse after discontinuation)
• Fertility impact and preservation options
• Need for ongoing medical monitoring
• The fact that long-term cardiovascular data beyond 10 years are limited

As the Endocrine Society guideline states directly: "We recommend that clinicians inform and counsel all individuals seeking gender-affirming hormone treatment about the potential effects on fertility and the options for fertility preservation before initiating treatment" [2].

Documenting Capacity and Consent

Standard medical consent documentation applies. There is no legal or ethical requirement for a psychiatric evaluation in an adult with decision-making capacity who meets the diagnostic criteria for gender dysphoria or gender incongruence. Providers who remain uncertain about capacity should follow their institution's standard capacity assessment process, not a transgender-specific referral pathway.

How to Use Elliot Page's Story Therapeutically in the Clinic

When a patient cites Elliot Page, the provider's job is to acknowledge the patient's connection to that story and then anchor the conversation in individualized data. Three steps work consistently:

Step 1: Validate the connection. Page's public disclosure has reduced stigma and increased health-seeking behavior. Saying "I understand why his story resonates with you" costs nothing and builds rapport.

Step 2: Distinguish narrative from protocol. Explain that Page's experience represents one data point, and that his timeline of changes, his formulation, and his dose are not publicly known. The patient's own physiology will determine their timeline.

Step 3: Move to assessment. Offer a structured evaluation: baseline labs (total testosterone, LH, FSH, hematocrit, lipid panel, blood pressure), a review of the Endocrine Society targets, and a shared decision about formulation. This converts a celebrity-driven inquiry into a clinical interaction with a defined next step.

Special Populations and Considerations

Adolescents

WPATH SOC8 does not set a minimum age for testosterone therapy but recommends that adolescents undergo a multidisciplinary assessment. Pubertal suppression with GnRH analogues (leuprolide, histrelin) is typically initiated at Tanner stage 2 to pause endogenous puberty before testosterone is started [3]. Bone density monitoring is particularly important in this population because the adolescent skeleton requires adequate sex hormone exposure to achieve peak bone mass.

Patients With Prior Cardiovascular Disease

A personal or family history of cardiovascular disease does not categorically contraindicate testosterone therapy, but it requires more frequent cardiovascular monitoring and lipid management. The decision should involve shared consultation with cardiology when prior MI, stroke, or significant atherosclerotic burden is present.

Patients Seeking Therapy After Oophorectomy

After bilateral oophorectomy, endogenous estrogen production is eliminated. Testosterone doses may need adjustment because some estrogen is normally produced peripherally from testosterone via aromatization. Bone density monitoring becomes more urgent. The Endocrine Society recommends maintaining testosterone levels in the male physiological range to support bone health in this group [2].